SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc.
(Nasdaq: HALO), a biopharmaceutical company developing and commercializing
products based on the extracellular matrix, today announced that David
Ramsay, Halozyme's Vice President and Chief Financial Officer, will present
at two investor conferences in February. Mr. Ramsay will present an
overview of the Company and its product candidates and 2008 milestones at
each conference.
-- 10th Annual BIO CEO & Investor Conference at The Waldorf-Astoria Hotel
in New York, NY on Tuesday, February 12, 2008 at 2:00 p.m. Eastern
Time (11:00 a.m. Pacific Time); and
-- Roth 20th Annual Growth Stock Conference to be held at the Ritz
Carlton Hotel in Laguna Niguel, CA on Thursday, February 21, 2008 at
11:00 a.m. Pacific Time (2:00 p.m. Eastern Time).
Interested parties can access a live audio webcast and accompanying
slides of the conference presentations via the Internet by visiting the
Investor Relations section of the Company's website at
http://www.halozyme.com. Archived presentations will be available on the
website for 30 days following the presentation date.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing
products based on the extracellular matrix for the drug delivery, oncology
and dermatology markets. The company's portfolio of products and product
candidates is based on intellectual property covering the family of human
enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a
novel drug delivery platform designed to increase the absorption and
dispersion of biologics. Its key partnerships are with Roche to apply
Enhanze Technology to Roche's biological therapeutic compounds for up to 13
targets and with Baxter to apply Enhanze Technology to Baxter's biological
therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has
received FDA approval for two products: Cumulase(R), for use in in vitro
fertilization, and HYLENEX, for use as an adjuvant to increase the
absorption and dispersion of other injected drugs and fluids. HYLENEX is
partnered with Baxter International Inc. The Company also has a number of
different enzymes in its portfolio that are targeting significant areas of
unmet need.
Halozyme Contact
David A. Ramsay
Chief Financial Officer
(858) 704-8260
SOURCE Halozyme Therapeutics, Inc.
 back to top
Related links:
http://www.halozyme.com
CONTACT:
David A. Ramsay, Chief Financial Officer of
Halozyme Therapeutics, Inc., +1-858-704-8260
|
